IMV Inc
TSX:IMV

Watchlist Manager
IMV Inc Logo
IMV Inc
TSX:IMV
Watchlist
Price: 1.12 CAD Market Closed
Market Cap: 9.2m CAD

Operating Margin
IMV Inc

-14 272.6%
Current
-15 020%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-14 272.6%
=
Operating Profit
-50.5m
/
Revenue
354k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CA
IMV Inc
TSX:IMV
9.2m CAD
-14 273%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
84.8B AUD
26%
NL
argenx SE
XBRU:ARGX
45B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
No Stocks Found

IMV Inc
Glance View

Market Cap
9.2m CAD
Industry
Biotechnology

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company is headquartered in Dartmouth, Nova Scotia and currently employs 97 full-time employees. The company went IPO on 2007-10-24. The firm is using its DPX delivery technology to achieve targeted immune activation. The Company’s lead candidate, maveropepimut-S, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its other candidates include DPX-RSV and DPX-COVID-19. Its DPX-RSV is a DPX-based vaccine candidate targeting the respiratory syncytial virus (RSV) strain A. The company is developing DPX-COVID-19, a vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using its DPX platform. The firm is also developing maveropepimut-S for the treatment of breast and ovarian cancer, as well as for Diffuse large B-cell lymphoma (DLBCL) and other malignancies.

IMV Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-14 272.6%
=
Operating Profit
-50.5m
/
Revenue
354k
What is the Operating Margin of IMV Inc?

Based on IMV Inc's most recent financial statements, the company has Operating Margin of -14 272.6%.

Back to Top